Bariatric Surgery and Metabolic Dysfunction-Associated Fatty Liver Disease: a 2022 Update.
Ioannis I LazaridisTarik DelkoPublished in: Praxis (2023)
Non-alcoholic fatty liver disease (NAFLD) has been recently termed metabolic dysfunction-associated fatty liver disease (MAFLD) to address the strong association with the metabolic syndrome. The prevalence of MAFLD is significantly increased in obese individuals and treatment of obesity is currently the cornerstone of management of MAFLD. Bariatric and metabolic surgery nowadays emerges as a key therapeutic strategy for the treatment of the MAFLD. This review aims to provide an update on the novel studies reporting the outcomes of bariatric surgery on the spectrum of MAFLD, from hepatic steatosis to cirrhosis.
Keyphrases
- weight loss
- bariatric surgery
- metabolic syndrome
- obese patients
- insulin resistance
- type diabetes
- oxidative stress
- minimally invasive
- roux en y gastric bypass
- emergency department
- body mass index
- gastric bypass
- cardiovascular risk factors
- skeletal muscle
- acute coronary syndrome
- atrial fibrillation
- smoking cessation
- surgical site infection